EGFR and adenocarcinoma: The populations with higher responses to gefitinib (females, non-smokers and patients with an adenocarcinoma histology) also have higher incidences of EGFR mutations (Kosaka et al, 2004; Pao et al, 2004; Shigematsu et al, 2005).